Selexis’ innovative technologies and world-class expert services significantly reduce the time, effort, and costs that are associated with developing high-performance mammalian cell lines for therapeutic protein production (e.g., MAbs, growth factors, enzymes).
The Selexis SUREtechnology Platform™ provides our partners with a single program that can be used for a wide range of applications, from drug discovery to biologics manufacturing. More than 95 global partners, representing the complete spectrum of life science enterprises—from research laboratories and biotech startups to big pharma—have utilized the unparalleled proprietary technology and highly specialized services of Selexis. SUREtechnology has generated nearly 80 drug candidates in clinical manufacturing and two commercial products, representing one of the industry’s largest portfolios.
Our SUREtechnology has made it possible to generate stable and high-performing manufacturing cell lines in approximately 3 months from the time of transfection, with productivity levels reaching 1-7 g/L for monoclonal antibodies (fed-batch culture in shake flask), reducing the need for larger bioreactor capacity.
We have also developed well-defined cell culture conditions, media, and seeding and feeding parameters (SUREfeed Strategy™) for our proprietary SURE CHO-M Cell Line™ and can carry out initial scale-up optimization into 1–2-L bioreactors. As a result, the Selexis SUREdevelopment Process™ improves productivity and jump starts the scale-up process for CMOs, resulting in faster biomanufacturing timelines and reduced development costs.